These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 18381782

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment.
    Briot K, Garnero P, Le Henanff A, Dougados M, Roux C.
    Ann Rheum Dis; 2005 Aug; 64(8):1137-40. PubMed ID: 15642695
    [Abstract] [Full Text] [Related]

  • 3. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U, Teichmann J, Müller-Ladner U, Strunk J.
    Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
    [Abstract] [Full Text] [Related]

  • 4. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P, Cotena C, Tessari G, Girolomoni G.
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment.
    Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, Esposito M, Tiberti S, Chimenti S, DE Lorenzo A.
    Dermatol Ther; 2011 Mar; 24(4):446-51. PubMed ID: 21910803
    [Abstract] [Full Text] [Related]

  • 7. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
    Brandt J, Haibel H, Reddig J, Sieper J, Braun J.
    J Rheumatol; 2002 Jan; 29(1):118-22. PubMed ID: 11824947
    [Abstract] [Full Text] [Related]

  • 8. Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study.
    Marinovic D, Dorgeret S, Lescoeur B, Alberti C, Noel M, Czernichow P, Sebag G, Vilmer E, Léger J.
    Pediatrics; 2005 Jul; 116(1):e102-8. PubMed ID: 15995009
    [Abstract] [Full Text] [Related]

  • 9. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 10. Early increase of abdominal adiposity in patients with spondyloarthritis receiving anti-tumor necrosis factor-α treatment.
    Hmamouchi I, Roux C, Paternotte S, Kolta S, Dougados M, Briot K.
    J Rheumatol; 2014 Jun; 41(6):1112-7. PubMed ID: 24737911
    [Abstract] [Full Text] [Related]

  • 11. Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy.
    Briot K, Roux C, Gossec L, Charni N, Kolta S, Dougados M, Garnero P.
    J Rheumatol; 2008 Feb; 35(2):310-4. PubMed ID: 18203315
    [Abstract] [Full Text] [Related]

  • 12. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P.
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [Abstract] [Full Text] [Related]

  • 13. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K, Deighton C.
    Rheumatology (Oxford); 2007 Mar 19; 46(3):439-41. PubMed ID: 17255137
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Body weight change since menopause and percentage body fat mass are predictors of subsequent bone mineral density change of the proximal femur in women aged 75 years and older: results of a 5 year prospective study.
    Blain H, Carrière I, Favier F, Jeandel C, Papoz L, EPIDOS Study Group.
    Calcif Tissue Int; 2004 Jul 19; 75(1):32-9. PubMed ID: 15129366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.